†Data are not intended to demonstrate clinical efficacy. In addition, the selected
antibiotics have not been compared in head-to-head studies.
‡Asbell PA, et al. JAMA Ophthalmol. 2020;138(5):439-450.
§The number of isolates tested against gatifloxacin were MRSA, 687; MRConS, 795; S
pneumoniae, 515; P aeruginosa, 667; and H influenzae, 707.
Table only includes antibiotics that are available in topical ophthalmic products with a bacterial
ARMOR, Antibiotic Resistance Monitoring in Ocular Microorganisms; CoNS, coagulase-negative
staphylococci; H influenzae, Haemophilus influenzae; MIC90, the minimum inhibitory
that inhibits the growth of 90% of indicated isolates; MRCoNS, methicillin-resistant CoNS; MRSA,
methicillin-resistant Staphylococcus aureus; P aeruginosa, Pseudomonas aeruginosa; S pneumoniae,
ARMOR surveillance study limitations2
Participating sites in the United States were invited to submit a prespecified number of isolates of
S aureus, CoNS, S pneumoniae, H influenzae and P aeruginosa cultured from eye infections. There is
potential for sampling bias due to the infrequent practice of culturing bacterial pathogens. The
application of system breakpoints to define susceptibility to ocular treatments, and thus the
applicability to topically applied antibiotics, may not be relevant. Because topical antibiotics are
rapidly eliminated from tears due to tear turnover, the antibiotic concentration in ocular tissue
may not be indicative of the actual concentration effect.
BESIVANCE: Dual targeting activity helps increase bactericidal potency while decreasing drug resistance1-3
*Clinical significance of these in vitro data has not been established.
llIn vitro resistance to besifloxacin occurs at a general frequency of <3.3 × 10-10 for S aureus and <7 × 10-10 for S pneumoniae.3